Ardelyx: Biotech Pioneer Tackling Mineral Metabolism Disorders
Ardelyx Inc. focuses on biotech drugs targeting mineral metabolism disorders, trading on Nasdaq with a $772M market cap while investing heavily in R&D for U.S. patients.
2 minutes to read

